Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLD for Previously Treated AL Amyloidosis
NCT00607581Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Feb 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in amyloid light chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Hematologic Response Rate at 3 months. Started Feb 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT00607581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607581.